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Background: Schistosomiasis is a parasitic disease that occurs in the tropics and subtropics. The mainstay of
control is preventive chemotherapy with praziquantel. In Africa, an estimated 230 million people require preventive
chemotherapy. In western Côte d’Ivoire, infections with Schistosoma mansoni are widespread. To provide an
evidence-base for programme decisions about preventive chemotherapy to sustain control of schistosomiasis, a
5-year multi-country study with different treatment arms has been designed by the Schistosomiasis Consortium
for Operational Research and Evaluation (SCORE) and is currently being implemented in various African settings,
including Côte d’Ivoire.
Methods/Design: We report the study protocol, including ethics statement and insight from a large-scale eligibility
survey carried out in four provinces in western Côte d’Ivoire. The study protocol has been approved by the ethics
committees of Basel and Côte d’Ivoire. A total of 12,110 children, aged 13–14 years, from 264 villages were screened
for S. mansoni using duplicate Kato-Katz thick smears from single stool samples. Among the schools with a S. mansoni
prevalence of 10-24%, 75 schools were selected and randomly assigned to one of three treatment arms. In each school,
three stool samples are being collected from 100 children aged 9–12 years annually and one stool sample from
100 first-year students at baseline and in the final year and subjected to duplicate Kato-Katz thick smears. Cost
and coverage data for the different intervention arms, along with environmental, political and other characteristics
that might impact on the infection prevalence and intensity will be recorded in each study year, using a pretested
village inventory form.
Discussion: The study will document changes in S. mansoni infection prevalence and intensity according to
different treatment schemes. Moreover, factors that determine the effectiveness of preventive chemotherapy will be
identified. These factors will help to develop reasonable measures of force of transmission that can be used to make
decisions about the most cost-effective means of lowering prevalence, intensity and transmission in a given setting.
The gathered information and results will inform how to effectively sustain control of schistosomiasis at a low level
in different social-ecological contexts.
Trial registration: ISRCTN99401114 (date assigned: 12 November 2014).
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Burden and transmission of schistosomiasis, with an
emphasis on Schistosoma mansoni in Africa
Human schistosomiasis, a disease caused by chronic
infection with parasitic trematodes of the genus Schisto-
soma, is endemic in 78 tropical and subtropical coun-
tries, 42 of which are located in Africa [1]. An estimated
779 million people are at risk of schistosomiasis, more
than 230 million are infected, 120 million are symptom-
atic and 20 million suffer from severe and debilitating
forms of schistosomiasis [2-5]. The burden of the disease
is essentially concentrated in Africa, where more than
90% of the infections worldwide occur [5-7]. Schisto-
somiasis is intimately connected with poverty, and hence,
the disease delays the social and economic development
in endemic countries [5,8-10].
The life cycle of schistosomiasis involves a phase of
sexual reproduction by adult schistosome worms in the
definitive human host, and an asexual phase in the inter-
mediate host, a specific freshwater snail. In Côte d’Ivoire,
for example, Biomphalaria pfeifferi is the only inter-
mediate host snail for Schistosoma mansoni [11]. From
the snail, cercariae are released into the surrounding
water and can invade humans through the skin. Infec-
tion with S. mansoni causes intestinal schistosomiasis.
Typical symptoms include blood in the stool, (bloody)
diarrhoea, chronic or intermittent abdominal pain, an-
aemia, general fatigue, weight loss, hepatomegaly, spleno-
megaly and marked eosinophilia [8,12]. Moreover, chronic
infection can impair children’s physical and cognitive
development and nutritional status [13]. Associations
of intestinal schistosomiasis with hepatitis, acquired im-
munodeficiency syndrome (AIDS) and malaria hyperten-
sion have been reported [14-16].
Several factors contribute to the spread of schistosom-
iasis. Demographic features, including age, gender, ethni-
city and socioeconomic status have a strong influence
on the spatial distribution of schistosomiasis, particularly
S. mansoni [17,18]. Tourism, construction and operation
of water resource developments (i.e. irrigation schemes
and dams) are associated with higher risks of S. mansoni,
explained by the creation of favourable conditions for
intermediate host snails and higher frequencies of human-
water contacts [5,19,20]. It is estimated that more than
100 million people at risk of schistosomiasis live in irriga-
tion schemes or in close proximity to reservoirs of large
dams [5]. Intense rainfall and flooding might be respon-
sible for the reintroduction of intermediate host snails to
areas from which schistosomiasis had previously been
eliminated [21].
Schistosomiasis control in Africa
According to the World Health Organization (WHO),
comprehensive schistosomiasis control programmes shouldinclude treatment of at-risk groups, provision of clean
water, adequate sanitation, hygiene education and snail
control [1]. The current mainstay of control is prevent-
ive chemotherapy – that is the periodic administration
of the antischistosomal drug praziquantel to entire at-
risk populations without prior diagnosis. The goal is to
cover at least 75% of those at risk of schistosomiasis by
preventive chemotherapy in 2020 [7]. The frequency of
preventive chemotherapy is guided by infection preva-
lence in specific age groups. In areas where the preva-
lence of Schistosoma infection in school-aged children
(5–14 years) is 50% or higher, entire communities
should be treated once every year; if the prevalence is be-
tween 10% and 50%, treatment is focussed on school-aged
children with a frequency once every two years; if the
prevalence is below 10%, school-aged children should be
treated twice, at school entry and again before they finish
schooling [22,23]. In Africa, approximately 35.5 million
people were treated with praziquantel in 2012 [1]. This
estimate accounts for a coverage of only 13.6% of school-
aged children. Hence, concerted efforts are needed to
massively scale-up preventive chemotherapy to reach the
75% coverage goal by the year 2020. In Côte d’Ivoire,
where both S. mansoni and S. haematobium are endemic
and many people suffer from intestinal or urogenital
schistosomiasis [17,24-29], no large-scale preventive
chemotherapy programme was in place prior to the onset
of this study in 2011 [28,30,31].
Operational research for schistosomiasis control
Further up-scaling of schistosomiasis control in the years
to come will not only need political commitment, na-
tional strategic plans, dedicated development partners,
functioning health systems and community volunteers,
but will also involve major costs. To assess which strat-
egy of preventive chemotherapy will provide the best
balance in terms of reduction in prevalence and intensity
of schistosome infection in school-aged children on one
hand, and costs on the other hand, the Schistosomiasis
Consortium for Operational Research and Evaluation
(SCORE; http://score.uga.edu/) designed a series of large-
scale, multi-country intervention studies. In response to a
request for proposals to gain and sustain control of schis-
tosomiasis in Africa, several investigators from Africa, in
partnership with colleagues from Europe and the United
States of America, put forward their ideas. The proposals
were evaluated by a panel of experts against predefined
criteria. Initially, three projects were selected under the
heading “Sustaining control of schistosomiasis”, focusing
either on S. mansoni (two projects; Côte d’Ivoire and
Kenya) or S. haematobium (one project; Niger). The over-
arching goal is to evaluate alternative approaches to pre-
ventive chemotherapy in areas with moderate prevalence
of infection at baseline (10-24% in school-aged children).
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in Niger has been terminated after two years due to an
issue with the randomisation of study villages.
Here, we summarise the relevant part of a harmonised
study protocol that is being followed by partners con-
ducting the sustaining control of schistosomiasis man-
soni studies in Côte d’Ivoire and Kenya. The field and
laboratory procedures for the sustaining S. mansoni
control project in moderate endemicity areas of Côte
d’Ivoire will be presented in greater detail, including
results of the initial eligibility survey, which guided the
selection of 75 communities or villages for subsequent
treatment interventions.
Goal, aims and objectives
The goal of the SCORE projects aiming at sustaining
control of schistosomiasis at a low level is to generate
an evidence-base for programme decisions about pre-
ventive chemotherapy-based approaches to sustain the
control of S. mansoni infections. The studies will de-
termine which strategy for preventive chemotherapy
provides the best balance in terms of cost and the re-
duction in prevalence and intensity of infection in
school-aged children after four years of intervention.
The studies are designed to answer the following ques-
tion: How can we sustain control of S. mansoni in
communities/villages with a moderate endemicity level
(prevalence of 10-24%, as assessed by a single stool
examination with duplicate Kato-Katz thick smears)?
Specifically, we are addressing the following research
questions:
 What combination of annual school-based treatment
(SBT) and “drug holidays” yields the best outcomes
for the lowest cost?
 What are the factors that determine the
effectiveness of preventive chemotherapy?
 Can reasonable measures of force of transmission be
developed that can be utilised to make decisions
about the most cost-effective means of lowering
prevalence, intensity and transmission in a given
setting?Figure 1 Study arms for the sustaining control of Schistosoma manso
SBT, school-based treatment; Holiday, no drug delivery.Methods/Design
Study design
The SCORE sustaining schistosomiasis control studies
are designed as randomised intervention trials with three
study arms. Each arm comprises 25 communities or vil-
lages. Hence, the studies will include 75 communities per
country. Communities will be provided with various com-
binations of SBT and “drug holidays” over a 4-year period,
followed by final data collection, analysis and dissemin-
ation of results in the fifth year. The intervention arms in
the sustaining schistosomiasis control studies are designed
as shown in Figure 1. In brief:
 schools of arm A will receive annual SBT for
four years;
 schools of arm B will receive SBT in the first two
years, followed by “drug holidays”; and
 schools of arm C will receive SBT in years 1
and 3, alternated by “drug holidays” in years 2
and 4.
Preventive chemotherapy with praziquantel is being
provided as single oral dose of 40 mg/kg, using a dose
pole. Standard praziquantel treatment exclusion criteria
apply [22]. No treatment will be provided during “drug
holidays” and no parasitological data are collected in
those years. During SBT, praziquantel will be adminis-
tered by trained teachers to all school-going children.
Children in all schools in the community will be treated,
and hence, children attending schools not otherwise
involved in the study will also receive treatment. Any
time SBT will take place, additional efforts will be made
to enhance treatment coverage, such as community
sensitization and mobilization efforts, radio announce-
ments, and other means of information, education and
communication (IEC) strategies. Non-school attendees
who span the same age range as school-going children
will also be invited for treatment. No other major treat-
ment strategies outside the education sector venue
will be implemented. The school attendance rates and
treatment coverage will be documented throughout
the study.ni studies in moderate endemicity areas (prevalence: 10-24%).
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and participants
The protocol for the sustaining schistosomiasis control
studies was developed through a series of expert consul-
tations, facilitated by the SCORE secretariat and its
scientific advisory board. The decision to choose three
intervention arms for the current studies took into con-
sideration formal sample size calculation and operational
feasibility. For sample size calculation, it was assumed
that the treatment interventions will reduce Schistosoma
prevalence in moderate endemicity areas from 25% to
10%. Analyses determined the minimum effect size that
may be detected with 90% power for a 2-sided α = 0.05
level test as a function of the number of children m
tested per village, the number n of villages sampled per
treatment, the overdispersion parameter φ, and the cor-
relation ρ between observations in year 1 at baseline and
in year 4 at the end of the study. The calculations re-
vealed that studying 20 communities or schools per arm
and evaluating 100 individuals per school would result
in minimum effect sizes of 5-12% with or without over-
dispersion. This minimum effect size was deemed rea-
sonable. To further increase the chance of detecting
differences between the interventions arms, the number
of the units of interventions, and hence, the number of
schools, was increased to 25 per arm. Taken together,
the trial protocol asked to examine 100 children aged
9–12 years every year whenever drug intervention will
be implemented as primary outcome. Additionally, 100
first-year students will be examined in years 1 and 5.
Eligibility of study communities
Sustaining schistosomiasis control studies will include
75 communities with an initial S. mansoni prevalence of
10-24%. Selection of these large numbers of communi-
ties has been determined through a rapid appraisal eligi-
bility survey. A single stool sample from each of 50
children aged 13–14 years has been subjected to dupli-
cate Kato-Katz thick smears [32,33]. Additional criteria
applied for eligibility determination are as follows. First,
a study community must have a primary school, because
the arms of the study are school-based and every partici-
pating community must be eligible to be randomised to
any of the study arms. However, it is permitted that a
study community may have more than one school. If
two nearby communities have schools with less than 100
children per school but they are similar in terms of ecol-
ogy and socioeconomic status, they can be combined for
purposes of this study and be considered as a single
study community. Second, two nearby communities that
share water sources and/or whose schools have over-
lapping catchment areas will not be considered sep-
arate villages for the purposes of this study; one of the
two schools will be chosen. Third, there is no pre-setpopulation requirement for the size of a community, as
long as it includes at least 100 children aged 9–12 years
who attend school. Fourth, preference is for settings that
have not recently been subjected to preventive chemo-
therapy targeting schistosomiasis. If communities have
been previously treated, historic treatment data should
be included where available. Fifth and finally, to the ex-
tent possible, study communities should be as similar as
possible in characteristics that could affect transmission
dynamics, including, for example, a history of past treat-
ment and the availability of water sources.
Eligibility of study participants
For the eligibility study to rapidly identify the 75 com-
munities with a baseline prevalence of 10-24%, children
were eligible to participate if they were 13 or 14 years
old and provided an informed consent sheet signed by
their parents. In the baseline and the yearly follow-up
surveys conducted to assess the change in prevalence
and intensity of Schistosoma infection in each interven-
tion arm, children aged 9–12 years who provide a written
informed consent from their parents will be included. Add-
itionally, in years 1 and 5, first-year students will provide
written informed consent from their parents and will par-
ticipate in the study.
Details of the sustaining S. mansoni control study in
western Côte d’Ivoire
Study area and population
The sustaining S. mansoni control study in Côte d’Ivoire
is being conducted by a team of researchers from the
Université Félix Houphouët-Boigny, who work in close col-
laboration with the Programme National de Lutte contre la
Schistosomiase, les Géohelminthiases et la Filariose
Lymphatique (PNL-SGF) at the Ministry of Health and
Public Hygiene, the ‘Centre Suisse de Recherches Scientifi-
ques en Côte d’Ivoire (CSRS), all based in Abidjan, and the
Swiss Tropical and Public Health Institute (Swiss TPH) in
Basel, Switzerland.
The study area is located in western Côte d’Ivoire in
the four regions Cavaly, Guemon, Haut-Sassandra and
Tonkpi (Figure 2). The area was chosen because it is a
well known S. mansoni focus [25] and our teams con-
ducted schistosomiasis research there since the mid-
1990s, including treatment of individuals found positive
upon Kato-Katz examination [17,24,28,29,34-37]. Cavaly,
Guemon and Tonkpi regions are located west of the
Sassandra River and belong to the district des Montagnes.
Ten departments of this district are included in our study:
Bangolo, Biankouma, Danané, Douékoué, Facobly, Guiglo,
Kouibly, Man, Sipilou and Zoukougbeu. The district des
Montagnes is a mountainous area with an average altitude
ranging between 300 m and slightly above 1,000 m. The
climate is humid tropical with two seasons. The rainy
Figure 2 Map of Côte d’Ivoire with the four study regions in the western part where the SCORE sustaining S. mansoni control project
is being implemented.
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Sassandra region is located East of the Sassandra River.
Zoukougbeu is the only department of that region which is
included in our study. Here, the average altitude ranges be-
tween 200 m and 300 m. The climate is sub-equatorial,
characterised by two rainy seasons. The long rainy season
occurs from March to July and the short rainy season from
September to October.
According to the national population census carried
out in 1998 (the most recent census at the time of writ-
ing the current piece), the total population in the study
area is 1.5 million people (unpublished data; Institut
National de la Statistique en Côte d’Ivoire). Most peoplebelong to one among the four ethnic groups: Bété, Guéré,
Wobé and Yacouba. People are mainly engaged in subsid-
ence farming (cassava, maize, plantain and rice). There is
also production of cash crops (coffee and cocoa) and a
small forestry industry in the town of Man [38].
The annual rainfall in the study area varies between
1,100 and 2,000 mm. The vegetation is composed of two
types of forests (semi-deciduous and evergreen mountain
forest). The average annual temperature is around 26°C.
Selection and randomisation of study villages
The 75 villages with a S. mansoni prevalence of 10-24%
in western Côte d’Ivoire were identified as follows. First,
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education authorities in the four study regions. The pur-
pose and procedures of the study were explained and a
total of 264 communities fulfilling the following criteria
were identified: (i) village has a school attended by at
least 100 children aged 9–12 years in grades 2–5 and 50
children aged at least 13 years in grades 4–6; (ii) village
and school had no recent history of preventive chemo-
therapy using praziquantel against schistosomiasis (within
the past 12 months); (iii) village is accessible also in the
rainy season; and (iv) it is safe for our teams to work in
the village. The latter issue was a real concern, as Côte
d’Ivoire suffered from a decade-long political unrest that
culminated in armed conflict and war in late 2010/early
2011 [39]. Before the onset of the surveys in each school,
we conducted a brief interview with the school teachers to
assess the selectability of the villages, according to the
aforementioned criteria. Then, schoolchildren in grades
1–6 were informed about the mode of transmission of
S. mansoni, its health impact and the importance of
the current project. Children aged 13 or 14 years were
randomly selected from grades 4–5 until the number
of children reached 50. In settings where less than 50
children aged 13–14 years were present, the sample
was completed with 12-year-old children, but these chil-
dren will not be enrolled in the subsequent randomised
controlled trial.
Children were asked to provide a written informed
consent from their parents or legal guardians. Children
with written informed consent were supplied with plastic
containers to collect a small amount of their own early
morning stool specimen. Collection containers wereFigure 3 Range of prevalence of S. mansoni infection in the 264 villag
S. mansoni endemicity areas (10-24%). At the unit of the school, we exa
smears from a single stool sample.labelled with unique identification numbers. The name,
sex, age and school grade of each child were recorded.
Stool samples were transferred to the Centre Hospitalier
Regional de Man for parasitological examination. From
each stool sample, duplicate Kato-Katz thick smears
were prepared on microscope slides using 41.7 mg tem-
plates [32,33]. After allowing the slides to clear for at least
60 min, they were examined under a microscope by
experienced laboratory technicians for the presence
of S. mansoni and soil-transmitted helminths (i.e. Ascaris
lumbricoides, hookworm and Trichuris trichiura).
The prevalence of S. mansoni was calculated for each
school. A total of 12,110 children submitted a stool sam-
ple that was subjected to duplicate Kato-Katz thick
smears. The prevalence at the unit of the school in the
eligibility survey ranged from 0% to 100% (Figure 3). In
brief, among the 264 schools, 157 (59.5%) had a S. man-
soni prevalence above 24%, 78 (29.5%) schools had a
prevalence ranging between 10% and 24%, whilst the
remaining 29 schools (11.0%) had a prevalence below 10%.
As shown in Figure 4, most of the villages meeting the sus-
taining control prevalence range (i.e. 10-24%) that were ul-
timately selected (n = 75) are located in the Guemon
region. The schools were randomly assigned to three inter-
vention arms using a computer-based randomisation pro-
cedure conducted by an independent statistician.
Data collection in the main study
Collection of stool samples and administration of a
questionnaire
At the beginning of the main activities of the sustaining
S. mansoni control study in the western part of Côtees screened in western Côte d’Ivoire to identify moderate
mined 50 children aged 13–14 years with duplicate Kato-Katz thick
Figure 4 Map showing point prevalence of S. mansoni in 264 schools of western Côte d’Ivoire, as determined by an eligibility survey
in late 2011/early 2012.
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village authorities and children’s parents. Detailed infor-
mation was provided about the forthcoming cross-
sectional parasitological and questionnaire surveys. Each
year, shortly before the annual parasitological survey,
teachers will be re-informed about the purpose and pro-
cedures of the study. Teachers assist by preparing class
lists, including name, age, sex and school grade. In each
school, children aged 9–12 years are enrolled from grades
2–6 until 100 pupils will be reached. Moreover, at base-
line and in the final year of the study, 100 pupils will berandomly selected from the class list of grade 1 and their
age will be recorded.
Before sample collection commences, the study is ex-
plained in lay terms to the selected children and they are
invited to provide three stool samples over consecutive
days. Stool samples are collected in 125 ml plastic con-
tainers. Children are asked to return the containers
within an hour, filled with an apricot-sized portion of their
own stool. We collect the containers and label them
with individual IDs. The stool collection procedure is
repeated over three consecutive days. Children without
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able to produce at least two stool samples are withdrawn,
but they receive praziquantel treatment as the other chil-
dren in the same village. For final analysis those children
who have written consent and results from at least four
Kato-Katz thick smears are included.
Upon visiting the school by our team, the community
leader is contacted and interviewed with a pre-tested
questionnaire to record characteristics of demography,
main activities, health system, water contact sites, and
sources of water and sanitary facilities in the village.
Demographic information includes the number of house-
holds and total population. The health system is charac-
terised by accessibility to health infrastructures, and
availability of praziquantel against schistosomiasis and
artemisinin-based combination therapy (ACT) against
malaria. Information pertaining to water contact sites
comprises the number of stagnant and non-stagnant
freshwater bodies. The questionnaire also allows deter-
mining which type of water the population uses for
drinking, bathing and cleaning. We also assess which
type of sanitary facilities the population uses (i.e. pit la-
trine, ventilated improved pit latrine, toilet or any other
kind of facilities).
Overall, the plan is to collect 22,500 stool samples
from children aged 9–12 years and 7,500 stool samples
from first-grade children at baseline (year 1) and at the
end of the study (year 5). In years 2, 3 and 4, a total of
15,000 stool samples will be collected from children
aged 9–12 years. Children on “drug holidays” will not be
subjected to stool examination.
Laboratory procedures to assess S. mansoni infection
Fresh stool samples are transferred to central laborator-
ies at the hospitals of Bangolo, Biankouma, Danané,
Douékoué, Guiglo, Kouibly and Man. The stool samples
are subjected to the Kato-Katz method [32,33]. In brief,
duplicate Kato-Katz thick smears are prepared from
each sample using standard 41.7 mg templates. After a
clearing time of at least 60 min, the thick smears will be
examined under a microscope by experienced laboratory
technicians. Eggs of S. mansoni and soil-transmitted hel-
minths (A. lumbricoides, hookworm and T. trichiura) are
counted and recorded for each species separately. For
quality control, 10% of the slides are randomly selected
and re-examined by a senior microscopist. The results
are compared with the results of the first examination
by the team. Slides identified with discrepant results
(e.g. S. mansoni egg-positive vs. egg-negative or differ-
ence of S. mansoni egg counts of more than 20%) are re-
examined until agreement has been reached. Given the
large number of slides processed in the eligibility sur-
vey, parts of the slides were transferred to Abidjan and
were examined microscopically within a maximum of3 months after stool collection. All record sheets will be
transferred to the Université Félix Houphouët-Boigny,
where data entry, cleaning and database management
take place.
SBT and assessment of coverage
District and community medical personnel are associ-
ated with the SBT in Côte d’Ivoire. Teachers and com-
munity health workers are trained to sensitize the
communities, to administer drugs to the children and to
monitor adverse events. Different sensitization tools are
implemented such as radio and television announcements,
along with other IEC strategies.
During SBT, praziquantel is administered by trained
teachers to all children attending school. Children in all
schools in the community are treated, even if the school
is not among the 75 schools where children are being
tested. Efforts are made to reach out to non-enrolled
children to enhance treatment coverage.
Treatment is supervised by physicians and implemented
by trained school teachers. Praziquantel tablets are deliv-
ered using a WHO dose pole [40]. Children are monitored
for adverse events for 4 hours after treatment and, if need
be, appropriate medical action is taken. Treatment will be
led by the PNL-SGF, and supported by staff from the
Programme National de Santé Scolaire et Universitaire
(PNSSU). Financial support to facilitate treatment is pro-
vided by SCORE, while praziquantel tablets are supplied by
the Schistosomiasis Control Initiative (SCI).
Data collection, management and statistical analysis
In the eligibility and baseline surveys, data are collected
on paper form, but then, starting at year 2, smartphones
have been utilised for data collection in the field and
laboratory. Data cleaning and management is done by
a designated database manager (PKY) at the Université
Félix Houphouët-Boigny in Abidjan. Demographic and
parasitological data directly entered in smartphones are
uploaded to a database maintained on a central server
(Open Data Kit) hosted by the SCORE secretariat at the
Task Force for Global Health in Atlanta, United States
of America. Data from questionnaire records will be en-
tered in Microsoft Excel (2010 Microsoft Corporation).
Statistical analyses will be carried out in STATA version
12 (StataCorp.; College Station, TX, USA). The primary
outcome will be the change in prevalence and intensity
of S. mansoni infection in the cohort of 9- to 12-year-
old children over the four years of intervention. For each
year, prevalence and infection intensity data will be cal-
culated as described below. The results from the differ-
ent study arms will be compared on an annual basis and
at the end of the 4-year intervention period.
Each child with at least one S. mansoni egg identified
in at least one of the Kato-Katz thick smears will be
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be determined for each child by calculating the arith-
metic mean S. mansoni egg counts from all Kato-Katz
thick smear readings and by multiplication with a
factor 24. The S. mansoni infection intensity will be
categorised according to WHO guidelines into light infec-
tion (1–99 EPG), moderate infection (100–399 EPG) and
heavy infection (≥400 EPG) [22].
School attendance rate will be documented throughout
the study. The treatment coverage will be determined by
(i) calculating the percentage of pupils treated among
the total children registered in the school and (ii) calcu-
lating the percentage of school-aged children not attend-
ing school who are treated according to data from
community health workers.
To guarantee the privacy of individuals, a separate and
confidential file will be kept, detailing names against ID
numbers. All data will be stored in purpose-built MS
Excel files with no names but only ID numbers and will
be kept by the data manager at the Université Félix
Houphouët-Boigny. A safety copy will be stored in a se-
cured locker. Only authorized persons will have access
to the data within the context of the project, and the
data will be backed-up regularly and safely. In addition,
all work stations of data entry clerks will be protected by
case-sensitive passwords and there will be no sharing of
any account or password information between staff and
other individuals not concerned with the project. When
discussing or showing the results of analyses in public
venues, the information will always be reported at an ag-
gregate level so that individual participants cannot be
identified.
Protocol review and ethical clearance
The study protocol has been approved by the institutional
research commissions of Swiss TPH in Basel and CSRS in
Abidjan. Ethical approval was obtained from the ethics
committees in Basel (reference no. EKBB 279/10; Basel, 21
October 2010) and Côte d’Ivoire (reference no. 1994
MSHP/CNER; Abidjan, 5 May 2010). The trial is registered
at controlled-trials.com (identifier: ISRCTN99401114; date
assigned: 12 November 2014). Informed consent is ob-
tained from parents or legal guardians of all pupils involved
in the study. Children are treated with praziquantel (40
mg/kg) using a dose pole [40] in the frame of SBT. Efforts
will be made to reach out to non-enrolled children.
The results of this study may be published, but sub-
jects’ names or identities will not be revealed. Records
will remain confidential and the results of tests will be
codified to prevent association with participants’ names.
Data entered into computerized files will be accessible
only by authorized personnel directly involved in the
study. Subject-specific information will be provided to
medical personnel only with the subject’s permission.Discussion
Human schistosomiasis is a chronic and debilitating dis-
ease responsible for an estimated global burden of 3.3
million disability-adjusted life years [41]. In Africa, 230
million people currently require preventive chemother-
apy [4]. The goal set by the WHO for the year 2020 is to
treat at least 75% of school-aged children at risk of
schistosomiasis with praziquantel as the only drug [7].
Various partners, institutions and pharmaceutical com-
panies have agreed in the London Declaration of 2012
that they will contribute to achieving this goal with do-
nation of praziquantel and other support to facilitate
and sustain drug administration at large scale [42]. The
SCORE study described here will provide an evidence-
base for programme decisions about the type and fre-
quency of preventive chemotherapy that is required to
sustain control of schistosomiasis mansoni in areas
where the baseline prevalence of infection ranges be-
tween 10% and 24%. The study will show for well char-
acterised settings across Africa which treatment scheme
(yearly treatment of school-aged children, or treatment
interspaced by holidays) will yield the best result and at
what cost. Moreover, factors that determine the effect-
iveness of large-scale deworming will be identified.
These factors will help to develop measures of force of
transmission that can be utilised to make decisions about
the most cost-effective means of lowering the prevalence
and intensity of Schistosoma infection and the force of
the transmission in a given setting. The data generated
might shape future treatment schedules to sustain the
control of schistosomiasis at low level elsewhere in sub-
Saharan Africa and perhaps in Asia and Latin America
where schistosomiasis also remains endemic, in prepar-
ation for a move to eliminate this disease in suitable
locations.
In western Côte d’Ivoire, infections with S. mansoni
are common [17,24,34] but until the mid-1990s, the ex-
tent of endemicity was not well understood. Some con-
trol efforts had been implemented in the 2000s, but due
to a decade-long socio-political crisis, control had been
interrupted [28,39]. The large eligibility study conducted
to select 75 villages with a moderate S. mansoni preva-
lence (10-24%) clearly revealed that S. mansoni in the
western part of Côte d’Ivoire is rampant; among 264
schools screened, 157 (59.5%) had a S. mansoni preva-
lence above 24%, while 78 schools (29.5%) were in the
desired prevalence range of 10-24% and only 29 schools
(11.0%) had a prevalence below 10%. The eligibility sur-
vey employed an insensitive diagnostic approach (i.e. du-
plicate Kato-Katz thick smears based on a single stool
sample). Had more intensive sampling and a more
sensitive diagnostic method been employed (e.g. three
stool samples subjected to triplicate Kato-Katz per stool
sample or a point-of-care circulating cathodic antigen
Assaré et al. BMC Public Health 2014, 14:1290 Page 10 of 11
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prevalence of S. mansoni would have been found [43-47].
In order to respect World Health Assembly (WHA)
resolution 54.19 endorsed in May 2001, which empha-
sises preventive chemotherapy targeting school-aged
children to control morbidity [48], and in view of a more
ambitions WHA resolution 65.21 put forth in May 2012,
the new declared goal is to move from morbidity control
to elimination of schistosomiasis [33,49]. Hence, author-
ities of Côte d’Ivoire have established the PNL-SGF in
June 2007 [28]. Hand-in-hand with the SCORE sus-
taining schistosomiasis control operational research
study reported here, the national schistosomiasis control
programme was reinforced, with additional support from
SCI. This study will provide data that may be used by
SCORE, SCI, WHO and other partners to deploy the best
tools and strategies to control morbidity due to schisto-
somiasis, and thus contribute to the reduction of poverty
in schistosomiasis-endemic countries.
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